ABSTRACT
In companion trials, 1708 premenopausal patients with stage II or III breast cancer were treated with modified radical mastectomy and eight cycles of CMF chemotherapy and randomized to postmastectomy radiotherapy or no further treatment (Paper 12) and 1375 postmenopausal patients with stage II or III breast cancer were treated with modified radical mastectomy and 1 year of tamoxifen and randomized to postmastectomy radiotherapy or no further treament (Paper 13). With a median follow-up of about 10 years, both trials showed about a 70% reduction in local recurrence and about a 30% reduction in overall mortality with radiotherapy.
